Qatar has some of the highest levels of metabolic disorders such as obesity and diabetes mellitus in the region” Dr Abdulla al-Hamaq, executive director of Qatar Diabetes Association (QDA) said.
“With the high prevalence of these diseases, it is very likely that our population will suffer from a variety of complications caused by them,” he pointed out.
Dr al-Hamaq was speaking at an event hosted by Novo Nordisk to introduce Saxenda (liraglutide 3 mg), a new medication for chronic weight management.
“We support innovation in the medical sector that helps treat these issues in our society,” he added.
According to World Health Organisation, around 72.2% of adults in Qatar are currently overweight, 34% are living with obesity. Many of these people suffer from weight-related comorbidities such as type 2 diabetes and high blood pressure, along with emotional distress and anxiety often associated with this disease.
“Significant clinical benefits and improvements in comorbidities can be seen with a weight reduction of 5-10% of body weight,” said Dr Stephen Atkin, Professor Of Medicine at Weil Cornell Medicine-Qatar and consultant endocrinologist at Hamad Medical Corporation in Doha.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Kahramaa, Siraj Energy sign agreements to build 800mw solar plant
ICC Qatar lauds Qatar's success in combating money laundering
Foreign minister meets UN official
FM meets Burundi counterpart
Institute of Public Administration, ACTA hold training courses
QNB names winners of QND promotion for personal loans
Huawei Mate30 Pro 5G coming to Qatar
QAC welcomes Shatharat students
AI and machine learning topics of lecture at NU-Q